This refresh
Data-driven refresh July 22, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,229 tickers); 1,778 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.7
Health Information Services · price $20.49 · 1Y $24.56 · 5Y $35.95 · 10Y $53.33
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 20.9x B+ · PEG 0.59 A-
Why now. DOCS’s AI‑driven workflow tool Ask is cementing the platform as the go‑to clinical knowledge hub for U.S. physicians, fueling a 13.1% YoY revenue growth and a 30.4% profit margin. Our model gives DOCS a Quality‑Growth score of 90.7, with Growth as the strongest pillar, underscoring the durability of this compounding engine. With a PE of 20.9 and a PEG of 0.59, the market already prices in modest upside, but the real catalyst is the expanding AI assistant usage that should keep earnings accelerating – the thesis hinges on that usage staying on its current trajectory.
Moat. DOCS locks in U.S. physicians through a network effect: the Doximity feed, peer updates, and the HIPAA‑compliant Ask assistant create a single‑point‑of‑truth that doctors can’t easily replace. The platform’s ROE of 20.6% stems from pricing power over a captive professional audience and premium sponsorships from pharma, which competitors can’t replicate without comparable scale and compliance infrastructure.
Risk. The Bull Rankings model’s reverse DCF assumes only ~2% annual free‑cash‑flow growth, far below the 13.1% revenue growth and the 30.4% margin, implying the current price is already stretched on optimism; a slowdown in AI adoption or a surge in competitor platforms would force the valuation down. A high beta of 1.29 magnifies market swings, and any dip in margin or rise in debt (currently 0.01 D/E) would confirm the bear case.
Horizon. 1-3 yr $24.56 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $35.95 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $53.33 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $218.36 · 1Y $269.61 · 5Y $394.73 · 10Y $585.56
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 12.5x A · PEG 0.62 A-
Why now. Adobe’s Digital Media segment, anchored by Creative Cloud subscriptions, is still expanding at 11.5% YoY revenue growth while delivering a rock‑solid 28.7% profit margin and generating $10.3 B of free cash flow. Our Bull Rankings model awards the stock an 89.6/100 quality‑growth score, with Quality as its strongest pillar, underscoring the durable earnings power that can keep compounding as the subscription base deepens. The thesis rests on the continued roll‑out of AI‑enhanced creative tools that lock in existing users and attract new enterprises, ensuring growth persists.
Moat. The Creative Cloud suite creates a high‑switching‑cost ecosystem for photographers, designers, and marketers, reinforced by Adobe’s integrated Digital Experience platform that bundles analytics, commerce and content management. This lock‑in drives an extraordinary 62.8% ROE, reflecting pricing power from category leadership in creative software and the ability to monetize add‑on services without significant incremental cost.
Risk. A 1.43 beta and a reverse‑DCF implied free‑cash‑flow growth of –4% per year signal that the market is pricing in aggressive optimism; if Adobe’s revenue growth stalls below the current 11.5% pace or margins compress, the valuation collapses. Additionally, a debt‑to‑equity of 0.61 adds leverage risk if cash generation falters, and a sustained slowdown would validate the bearish view that the stock is over‑priced relative to its growth prospects.
Horizon. 1-3 yr $269.61 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $394.73 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $585.56 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 89
Software - Infrastructure · price $14.26 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.3x B+ · PEG 0.48 A
Why now. DLocal’s cross‑border pay‑in platform for e‑commerce, streaming and ride‑hailing merchants is exploding, delivering 46.6% revenue growth YoY while keeping a healthy 18% profit margin and a stellar 34.6% ROE. Our Bull Rankings model awards a Quality‑Growth score of 89, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the continued rollout of its “dLocal for Platforms” suite that locks merchants into a single‑payment hub, fueling relentless top‑line expansion.
Moat. The platform’s breadth—supporting international cards, bank transfers, direct debit and hundreds of alternative payment methods—creates a high switching cost for merchants who need a unified solution across dozens of emerging markets. This network effect, combined with pricing power that drives a 34.6% ROE, locks in recurring fees and protects margins from competitive erosion.
Risk. The market is pricing in aggressive free‑cash‑flow growth: our reverse DCF implies a -7% annual FCF growth rate, which is at odds with the current 46.6% revenue surge and suggests optimism that may be unsustainable if growth decelerates or dilution from new share issuances intensifies. A bear‑case trigger would be a slowdown in merchant acquisition or a widening of the PEG ratio above 1, eroding the growth premium.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
4. INTU — Intuit Inc. · score 88.6
Software - Application · price $284.47 · 1Y $462.53 · 5Y $677.20 · 10Y $1,005
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.4x A- · PEG 0.75 A-
Why now. Intuit’s QuickBooks Online platform is cementing its dominance in the SMB financial‑management market, driving a 15.1% YoY revenue growth and a 21.9% profit margin that fuels a $7.8B free‑cash‑flow generation engine. Coupled with a low 0.33 debt‑to‑equity ratio and a PEG of 0.75, the business compounds earnings at a pace that far outstrips the reverse‑DCF implied -6% FCF growth, meaning the market is under‑pricing the sustainable growth runway. The thesis rests on QuickBooks’ sticky subscription base continuing to expand across the $250‑$921 analyst target range.
Moat. QuickBooks and Mailchimp lock small‑ and mid‑market firms into an integrated ecosystem of accounting, payroll, payments and marketing tools, creating high switching costs and cross‑sell leverage. The 22.2% ROE stems from pricing power in a category where Intuit commands the preferred solution for tax‑time compliance and cash‑flow management, a moat competitors struggle to replicate quickly.
Risk. The premium valuation—P/E of 17.4 versus sector averages—assumes growth will stay above 15% while margins remain near 22%; any slowdown in QuickBooks adoption or pricing pressure from emerging fintech rivals would compress the margin and push the P/E to historic lows. A bear signal would be a dip in revenue growth below 10% YoY, which would validate the market’s current over‑optimism.
Horizon. 1-3 yr $462.53 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $677.20 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,005 if current growth sustains into durable earnings power.
5. LRN — Stride, Inc. · score 87
Education & Training Services · price $84.22 · 1Y $96.85 · 5Y $141.80 · 10Y $210.35
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.2x A- · PEG 0.48 A
Why now. Stride’s integrated virtual‑school platform is the engine of growth – its proprietary curriculum and enrollment‑tracking software lock districts into a bundled solution that scales with every new student. The business is expanding revenue at 10.9% YoY, converting that into a healthy 12.2% profit margin and generating $414 m of free cash flow on a $3.6 bn market cap, which fuels a 13.2× P/E and a 0.48 PEG. The thesis rests on the continued compounding of district enrollments in blended public schools, a tailwind that should keep the growth engine humming.
Moat. The moat lives in the end‑to‑end package for virtual and blended public schools – curriculum, learning‑management software, progress tracking and professional services all flow from a single vendor. Switching costs are high because districts must re‑train staff and re‑integrate data pipelines, and Stride’s 18.8% ROE shows it extracts pricing power from this lock‑in. The proprietary content and data platform are not easily replicated, protecting margins as the school‑district base expands.
Risk. The Bull Rankings model forces a reverse‑DCF that assumes a –10% annual free‑cash‑flow decline for a decade, a stark contrast to the 10.9% revenue growth the company just delivered; if enrollment growth stalls or districts pull back on virtual spending, the price, already perched at 49% of its 52‑week high, could tumble. The biggest red flag is that the valuation is betting on sustained upside in a market where public‑school budgets are cyclical and funding reforms could curtail new contracts. A slowdown in district adoption would validate the bearish view and crush the upside.
Horizon. 1-3 yr $96.85 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $141.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $210.35 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 86.9
Drug Manufacturers - Specialty & Generic · price $172.69 · 1Y $202.56 · 5Y $296.57 · 10Y $439.94
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.6x B · PEG 0.51 A-
Why now. NBIX’s growth engine is anchored by its FDA‑approved rare‑disease franchise – INGREZZA for tardive dyskinesia and Orilissa for endometriosis – which together fuel a 28.6% YoY revenue surge and a 21.6% profit margin. Our Bull Rankings model awards a Quality‑Growth score of 86.9 with Growth as the strongest pillar, underscoring the durability of this compounding revenue stream, while a PEG of 0.51 signals that the market still undervalues the growth trajectory. The thesis rests on continued market‑share gains in these niche indications, driving sustained double‑digit top‑line growth.
Moat. NBIX’s moat stems from its deep IP protection and specialist positioning in neurological and endocrine disorders, where INGREZZA and Orilissa face limited generic competition and benefit from strong physician adoption. The company’s 19.6% ROE reflects pricing power derived from being a category leader in these underserved markets, creating a barrier for new entrants who lack comparable clinical data and reimbursement footholds.
Risk. The primary risk is the elevated valuation: a PE of 26.6 is high for a specialty biotech, implying the market has already priced in strong growth; a slowdown in the 28.6% revenue growth rate would force a re‑rating. Additionally, any margin compression that pushes profit margin below the current 21.6% level would trigger a sell‑off.
Horizon. 1-3 yr $202.56 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $296.57 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $439.94 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 86
Semiconductors · price $212.06 · 1Y $302.83 · 5Y $443.37 · 10Y $657.71
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 32.5x B · PEG 0.57 A-
Why now. NVIDIA’s AI‑accelerated data‑center platform is the engine of its growth, with the Compute & Networking segment powering the exploding demand for generative‑AI workloads. Revenue is surging +70.7% YoY, profit margins sit at a staggering 63%, and ROE is an eye‑popping 81.7% — a rare trio that fuels compounding cash flow. The bull case rests on the continuation of this AI‑driven revenue runway, which will keep the stock compounding at double‑digit rates.
Moat. NVIDIA’s moat stems from its integrated GPU‑plus‑software stack that locks in data‑center customers; switching to a rival requires redesigning both hardware and AI frameworks, a costly and time‑consuming move. The company’s pricing power in the high‑margin AI accelerator market translates into ROE above 80%, underscoring how its IP and ecosystem generate outsized returns that rivals can’t quickly replicate.
Risk. The stock trades at a lofty PE of 32.5 and a beta of 2.21, meaning any slowdown in AI spend or a broader market pull‑back could hammer valuation multiples. If revenue growth decelerates below the current 70.7% pace, the implied 49% FCF growth in our reverse‑DCF model becomes unsustainable, and the high volatility would trigger a sharp sell‑off. A miss on data‑center demand would be the decisive trigger for the bear case.
Horizon. 1-3 yr $302.83 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $443.37 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $657.71 if current growth sustains into durable earnings power.
8. TTD — The Trade Desk, Inc. · score 85.7
Advertising Agencies · price $17.58 · 1Y $24.32 · 5Y $35.61 · 10Y $52.82
FCF $842m C+ · Rev +15.5% B+ · D/E 0.17 A- · P/E 20.0x B · PEG 0.87 B+
Why now. The bull case hinges on The Trade Desk’s dominance in programmatic CTV advertising, a segment exploding as brands shift spend to over‑the‑top video. Its platform drives $842m of free cash flow on a $8.3b market cap while revenue is still climbing 15.5% YoY, giving the business a powerful compounding engine. With a PEG of 0.87, the growth premium is already baked in, but the real catalyst is the continued migration to addressable video, which should keep the 14.6% profit margin and 17.6% ROE expanding for years to come. The thesis rests on sustaining that high‑margin, high‑growth ad spend cycle.
Moat. The Trade Desk’s moat lies in its unified, data‑rich platform that serves agencies and advertisers across CTV, display, audio and digital‑out‑of‑home, creating deep integration and high switching costs. Its ability to deliver granular, cross‑device measurement gives clients pricing power that translates into the 17.6% ROE, a return that stems from category leadership in programmatic video buying. No competitor can replicate the breadth of inventory and real‑time optimization without rebuilding a comparable data stack.
Risk. The bear case centers on the steep valuation: a forward P/E of 20 is high for a growth name, and the Bull Rankings model’s reverse DCF implies a -6% annual free‑cash‑flow growth rate for the next decade—far below the 15.5% revenue growth currently reported. If CTV spend stalls or macro‑economic pressure forces advertisers back to legacy TV, margins could compress and the 14.6% profit margin would erode, sending the stock back toward its 52‑week low of $16.98. A sustained drop in FCF growth would confirm the downside.
Horizon. 1-3 yr $24.32 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $35.61 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $52.82 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.6
Information Technology Services · price $26.83 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.1x A- · PEG 0.88 B+
Why now. EXLS is a high‑growth AI‑driven claims and underwriting platform that is rapidly expanding its insurance‑tech footprint, delivering 13.4% YoY revenue growth, a robust 32.3% ROE, and $297 million of free cash flow—all at a reasonable PE of 17.1. The Bull Rankings model flags Growth as its strongest pillar (85.6 score), and the compounding of AI‑enabled services in the Insurance segment underpins a durable earnings runway. The thesis rests on the ability to keep scaling these high‑margin digital solutions.
Moat. EXLS’s moat stems from its AI‑powered claims management suite that locks in large insurers and health providers, creating high switching costs and pricing power that fuels a 32.3% ROE. The integrated analytics across Insurance, Healthcare, and Banking make the platform indispensable, limiting competitors’ ability to replicate its data depth and client relationships quickly.
Risk. The bear case centers on the modest leverage (debt‑to‑equity 0.67) and a valuation that already assumes near‑term acceleration—its reverse DCF implies a -2% annual FCF growth, yet revenue is only growing at 13.4% and margin pressure could erode the 11.7% profit margin. A slowdown in AI adoption or a pricing squeeze would push the PE above sector norms, and a breach of the 0.84 beta could amplify downside. Confirmation would be a miss on quarterly revenue growth or a widening of the debt ratio.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
10. HRMY — Harmony Biosciences Holdings, Inc. · score 85.1
Biotechnology · price $34.86 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.1x A- · PEG 0.65 A-
Why now. Harmony’s dominant market share with WAKIX in the U.S. narcolepsy space fuels a revenue runway that’s already expanding at 20.7% YoY, while the drug’s 16.2% profit margin converts that growth into cash, evidenced by a robust $342 m free‑cash‑flow. The pipeline—Phase 3 PWS and Phase 2 DM1—adds a binary upside that compounds the current earnings base, making the stock a high‑growth compounder. The thesis hinges on WAKIX’s continued pricing power and the near‑term FDA milestones that will unlock the next growth wave.
Moat. WAKIX’s novel mechanism of action and FDA‑approved status give Harmony a protected position in the rare‑neurology niche, where switching costs are high because clinicians and patients rely on a single, proven therapy for excessive daytime sleepiness. The company’s exclusive patents on pitolisant and its gastro‑resistant formulation create a barrier that competitors cannot quickly replicate, securing pricing power and steady cash conversion.
Risk. The bear case centers on the concentration risk of relying on WAKIX as the primary revenue driver; any adverse trial outcome in the PWS or DM1 programs would stall growth, and the current PE of 14.1 already reflects premium pricing for a single‑product business. A slowdown in revenue growth or margin compression would push the valuation into over‑optimism, and a missed regulatory milestone would confirm the downside.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
11. ADMA — ADMA Biologics, Inc. · score 84.7
Biotechnology · price $8.38 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.3x A · PEG 0.63 A-
Why now. ADMA’s compounding engine is its specialty IVIG franchise – BIVIGAM and ASCENIV – which rides a steadily expanding immune‑deficiency market, delivering 11% YoY revenue growth, a razor‑thin 32.4% profit margin and a stellar 42.4% ROE. The Bull Rankings model flags Growth as its strongest pillar (90), meaning the business’s earnings are set to keep accelerating, and the current price already embeds only a modest 2% free‑cash‑flow growth, leaving ample upside. The thesis rests on the continued outperformance of the IVIG segment as a high‑margin, repeat‑use therapy.
Moat. ADMA controls its own plasma collection centers, securing a captive source of high‑quality plasma that rivals cannot quickly replicate, and translates that supply advantage into pricing power in the IVIG space, reflected in a 42.4% ROE. This vertical integration creates a cost barrier and a reliable customer base of hospitals and immunology clinics that depend on ADMA’s proprietary plasma‑derived products.
Risk. The bear case centers on leverage and the looming risk that revenue growth stalls; a debt‑to‑equity of 1.11 signals a relatively heavy capital structure that could strain cash flow if growth slows below the modest 2% implied by the reverse‑DCF. A contraction in IVIG demand or a regulatory setback would push the P/E of 12.3 higher relative to earnings, confirming the downside. The key trigger would be a quarterly revenue growth miss that pushes the 52‑week low of $7.21 back into view.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
12. PRDO — Perdoceo Education Corporation · score 84.6
Education & Training Services · price $29.41 · 1Y $33.82 · 5Y $49.52 · 10Y $73.46
FCF $225m C · Rev +17.7% B+ · D/E 0.12 A- · P/E 11.2x A · PEG 0.65 A-
Why now. The bull case hinges on AIUS’s booming health‑sciences pipeline, where enrollment in nursing and healthcare management programs is fueling a 17.7% YoY revenue growth and a 19.9% profit margin. Coupled with a solid PE of 11.2x, the business can reinvest cash into buybacks and a rising dividend, compounding earnings at a rate that outpaces peers. Our Bull Rankings model gives PRDO an 84.6/100 quality‑growth score—its strongest pillar, Quality, reflects the durable, accredited curriculum that locks in students, and that is the engine of the thesis.
Moat. PRDO’s moat lives in its accredited, career‑oriented programs across CTU, AIUS and USAHS, which create high switching costs for students seeking federal aid and employer‑linked pathways. The 17% ROE stems from pricing power in niche health‑science tracks where few competitors can match the combined online‑blended delivery and industry partnerships, locking in tuition revenue for years.
Risk. The bear case is that the market is pricing in an unsustainable -16% annual free‑cash‑flow decline over the next decade, a stark mismatch to the 17.7% revenue expansion and 19.9% margin cushion, implying over‑optimism that could evaporate if enrollment slows or regulatory caps hit online providers. A single analyst’s $44 target also signals thin coverage; a miss on growth would trigger a sharp re‑rating and break the upside.
Horizon. 1-3 yr $33.82 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $49.52 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $73.46 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 83.4
Auto & Truck Dealerships · price $33.67 · 1Y $37.77 · 5Y $55.30 · 10Y $82.03
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 17.7x B+ · PEG 1.07 B+
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin revenue stream by letting shoppers start purchases online, fueling a 14% revenue growth and driving a 15.9% profit margin. Coupled with a stellar ROE of 62.9%, the business compounds earnings at a pace few peers can match, making the next 12‑months a decisive growth window.
Moat. The dealer‑subscription model creates a two‑sided network: millions of car shoppers feed a dense dealer inventory, locking in recurring fees that are hard for rivals to replicate without comparable scale. This network effect underpins the 62.9% ROE, reflecting pricing power that stems from CarGurus’ category leadership in the online automotive marketplace.
Risk. A reverse‑DCF shows the market is assuming a negative -2%/yr free‑cash‑flow growth for the next decade, yet the stock trades at a forward P/E of 17.7, implying optimism that may be overstated given a debt‑to‑equity of 0.79 and a beta of 1.18. A slowdown in dealer subscriptions or a rise in financing costs could push the valuation lower, and a breach of the 52‑week low ($26.39) would confirm the downside.
Horizon. 1-3 yr $37.77 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $55.30 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $82.03 if current growth sustains into durable earnings power.
14. RMD — ResMed Inc. · score 83.3
Medical Instruments & Supplies · price $192.91 · 1Y $247.93 · 5Y $363.00 · 10Y $538.48
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 18.6x A- · PEG 1.17 B+
Why now. ResMed’s dominance in cloud‑connected sleep diagnostics – exemplified by the ApneaLink Air and NightOwl devices – fuels a virtuous cycle of recurring software revenue, underpinned by 10.3% revenue growth, a robust 27.4% profit margin, and $1.8 B of free cash flow. With a PEG of 1.17 and a buy recommendation from 15 analysts, the company is primed to compound earnings as home‑based sleep testing expands, making the growth engine the single decisive catalyst.
Moat. The integrated hardware‑software platform creates high switching costs for sleep clinics and hospitals; once a patient’s data lives in ResMed’s cloud, clinicians stay locked in. This ecosystem, combined with pricing power that drives a 23.4% ROE, stems from category leadership in both diagnostic devices and the residential care software suite, a combination rivals cannot replicate quickly.
Risk. The Bull Rankings model flags a reverse‑DCF implied 0% free‑cash‑flow growth over the next decade, yet the company is currently delivering 10.3% top‑line growth; any slowdown would expose the stock’s elevated P/E of 18.6 as over‑optimistic. A miss on growth expectations would instantly validate the bearish view that the market has over‑priced future cash generation.
Horizon. 1-3 yr $247.93 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $363.00 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $538.48 if current growth sustains into durable earnings power.
15. DXCM — DexCom, Inc. · score 83.1
Medical Devices · price $71.43 · 1Y $85.75 · 5Y $125.55 · 10Y $186.24
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 30.7x B · PEG 1.39 B
Why now. The bull case hinges on the unstoppable adoption of Dexcom’s next‑gen CGM platform, the G7, which is rapidly winning over endocrinologists and diabetes clinics worldwide. The G7’s 19.3% profit margin, 31.5% ROE and 16.1% YoY revenue growth demonstrate a high‑margin, high‑return engine that our model flags with a Growth pillar of 96, driving a Quality‑Growth score of 83.1. As the market ramps up CGM penetration, that compounding profit engine will keep accelerating – the thesis rests on the G7’s ability to capture the expanding diabetes management market.
Moat. Dexcom’s moat derives from its integrated CGM ecosystem – the G7 hardware paired with Dexcom Share and Follow apps – which locks patients and clinicians into a data‑rich platform that is hard to replicate. The 31.5% ROE reflects pricing power earned from being the de‑facto standard for continuous glucose monitoring among endocrinologists, creating switching costs for both providers and patients. This ecosystem, combined with FDA‑cleared technology, gives Dexcom a durable competitive edge.
Risk. The bear case centers on the premium valuation: a forward P/E of 30.7 is well above the sector average, and the Bull Rankings model’s Value pillar of only 68 signals that the market may be over‑pricing future growth. If revenue growth stalls below the current 16.1% YoY pace, the implied 18% free‑cash‑flow growth in our reverse DCF becomes untenable, forcing the stock toward its 52‑week low of $54.11. A slowdown in G7 adoption or aggressive pricing from rivals would confirm this risk.
Horizon. 1-3 yr $85.75 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $125.55 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $186.24 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 83
Information Technology Services · price $86.57 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.4x A · PEG 0.46 A
Why now. EPAM’s digital platform engineering franchise is exploding in the cloud‑migration wave, driving a 14.2% revenue growth YoY while delivering a lean PE of 12.4x and a robust $544 m free‑cash‑flow. Our Bull Rankings model awards the stock an 83/100 Quality‑Growth score, with Value as the strongest pillar, underscoring the cheapness relative to its growth trajectory. The bull case hinges on the continued secular demand for cloud services and AI‑enabled platforms that will keep compounding earnings well above the reverse‑DCF implied -4% FCF growth.
Moat. EPAM’s moat lies in its end‑to‑end engineering services—from requirements analysis to smart‑automation—creating deep integration with large enterprise clients that face high switching costs for mission‑critical platforms. Its 11.3% ROE reflects pricing power earned by delivering bespoke cloud and AI solutions that competitors can’t replicate quickly without comparable talent and delivery frameworks.
Risk. The bear case focuses on the modest quality score (72) and the low debt‑to‑equity of 0.08, which may mask execution risk as the company scales its high‑margin services; a 1.43 beta adds market volatility, and the reverse‑DCF’s implied -4% FCF growth suggests analysts are already pricing in aggressive growth that could stall. A slowdown in cloud spend or a missed earnings beat would trigger a sell‑off, confirming the bear thesis.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
17. VEEV — Veeva Systems Inc. · score 82.3
Health Information Services · price $184.55 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 32.7x C+ · PEG 0.85 B+
Why now. Veeva’s Veeva Commercial Cloud, anchored by the Vault CRM Suite, is driving a relentless 16.2% YoY revenue growth while delivering a 28.4% profit margin and a sub‑1.0 PEG at 0.85. Our model’s strongest pillar—Growth—shows a 94 score, and the reverse‑DCF implies only a 7% annual free‑cash‑flow expansion, well below the actual growth rate, meaning the market is under‑pricing the compounding power of its cloud platform. The thesis hinges on this growth premium persisting as life‑science firms deepen their reliance on Veeva’s integrated data and analytics stack.
Moat. The Vault CRM Suite locks pharmaceutical and biotech customers into a single, regulated data repository, creating high switching costs and network effects across Veeva’s Data Cloud (OpenData, Link). Coupled with a 12.9% ROE generated from a near‑zero debt profile (Debt/Equity 0.01), Veeva leverages its industry‑specific compliance expertise that rivals cannot replicate quickly, sustaining pricing power in a niche market.
Risk. At a PE of 32.7 and a price still 40% below its 52‑week high, the market may be over‑optimistic about future growth; any slowdown from the current 16.2% revenue pace would make the valuation look stretched. A modest rise in beta to 1.2 or a margin dip below 28% would trigger a sell‑off, and the key risk signal would be a quarterly revenue growth falling under 10%, confirming a deceleration.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
18. ACN — Accenture plc · score 81.4
Information Technology Services · price $140.09 · 1Y $178.89 · 5Y $261.91 · 10Y $388.53
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 11.2x A · PEG 1.02 B+
Why now. Accenture’s unrivaled position in cloud‑enabled digital transformation drives a compounding engine anchored in its $12.6B free‑cash‑flow generation, 24.4% ROE and a solid 6.7% revenue growth YoY; the Bull Rankings model awards a Quality‑growth score of 81.4, with Quality as the strongest pillar, underscoring the durability of its high‑margin consulting and AI‑cloud services. This combination makes the stock a high‑quality growth compounder that can sustain earnings acceleration well beyond the market’s 1‑yr consensus target of $178.89.
Moat. Accenture’s end‑to‑end delivery platform—spanning strategy, systems integration, AI, cloud and managed services—creates deep switching costs for Fortune‑500 clients across finance, supply‑chain and HR functions, locking in multi‑year contracts that fuel its 24.4% ROE by extracting pricing power from category leadership in digital transformation.
Risk. The Bull Rankings model flags Growth as the weakest pillar, and the reverse‑DCF implies a -13% annual FCF growth rate baked into today’s price—far above the actual 6.7% revenue growth, meaning any slowdown or margin compression would expose the stock to a valuation cliff; a sustained dip in the 10‑yr target would confirm the bear case.
Horizon. 1-3 yr $178.89 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $261.91 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $388.53 if current growth sustains into durable earnings power.
19. APP — AppLovin Corporation · score 80.5
Advertising Agencies · price $412.48 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 35.9x C+ · PEG 1.18 B+
Why now. AppLovin’s growth engine is its MAX in‑app bidding platform, which fuels a staggering 66.4% YoY revenue growth and drives a 64.3% profit margin that translates into $4.4B of free cash flow. Our Bull Rankings model flags Growth as the strongest pillar (98) and the reverse‑DCF shows the market pricing in a relentless ~39% annual FCF expansion for a decade—an assumption that can only hold if MAX continues to dominate mobile inventory auctions. The thesis rests on the persistence of this high‑margin, AI‑powered bidding moat.
Moat. MAX creates a real‑time competitive auction that locks publishers into AppLovin’s ecosystem, making it costly to switch to rival ad stacks, while Adjust’s measurement suite deepens developer reliance on the platform’s data insights. This combination of lock‑in and superior analytics gives AppLovin a defensible edge that competitors can’t replicate quickly.
Risk. The stock trades at a lofty PE of 35.9 and a beta of 2.48, meaning any slowdown in the 66% revenue surge or a dip in margins would sharply erode valuation; the 1.63 debt‑to‑equity ratio adds leverage risk if ad spend contracts. A sustained deceleration in growth or a widening of margins would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
20. META — Meta Platforms, Inc. · score 79.6
Internet Content & Information · price $627.17 · 1Y $826.01 · 5Y $1,209 · 10Y $1,794
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 22.8x B · PEG 0.94 B+
Why now. Meta’s Family of Apps continues to dominate global social engagement, driving a 26.2% YoY revenue growth and a 32.8% profit margin that fuels a massive $48.3 B free‑cash‑flow engine. The platform’s deep network effects and expanding ad inventory in both Facebook and Instagram lock in recurring spend, ensuring compounding earnings as users and advertisers grow together. The thesis rests on the relentless scaling of ad‑driven cash flow across its FoA segment.
Moat. Meta’s moat is the entrenched network effect of its Family of Apps, where billions of users generate data that creates a virtuous cycle of higher ad relevance and pricing power, delivering a ROE of 29%. This high return is anchored by the platform’s ability to monetize attention at scale, a capability that rivals cannot replicate quickly without comparable user bases.
Risk. The bear case centers on a valuation premium and market volatility: a forward P/E of 22.8 and a beta of 1.25 suggest the stock is priced for continued acceleration, yet any slowdown in ad spend or regulatory headwinds could compress margins and erode the free‑cash‑flow runway. A breach of the 52‑week low at $520.26 would confirm the downside risk and invalidate the growth narrative.
Horizon. 1-3 yr $826.01 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,209 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,794 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 79.5
Internet Retail · price $1799.21 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 47.5x C · PEG 1.12 B+
Why now. MercadoLibre’s Mercado Pago ecosystem is the growth engine, fueling a 36.4% YoY revenue surge and delivering $11.8B of free cash flow while the platform scales across Brazil, Mexico, Argentina and beyond. The Bull Rankings model rates its Growth pillar at a perfect 100, driving a 79.5 overall quality‑growth score, and the stock trades at a forward‑PE of 47.5x, reflecting confidence that the payments and credit suite will keep compounding. The thesis hinges on the relentless expansion of Mercado Pago’s credit and investment services, which should keep the revenue runway open for the next decade.
Moat. The moat lives in the integrated Marketplace‑to‑Pago loop: sellers rely on Mercado Pago for seamless checkout, while buyers stay for the trusted credit and investment products, creating a high‑switching‑cost network effect. This synergy fuels a ROE of 26.4%, generated by pricing power in Latin America’s leading e‑commerce platform and the ability to cross‑sell financial services at scale.
Risk. The bear case centers on the lofty valuation; a PE of 47.5x is far above regional peers and the model’s reverse‑DCF implies a -7% annual FCF growth rate, meaning any slowdown in the 36% revenue growth or margin compression would expose the stock to a sharp correction. A rise in debt‑to‑equity above 1.7 or a beta‑driven market sell‑off would confirm the downside.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
22. PODD — Insulet Corporation · score 79
Medical Devices · price $158.93 · 1Y $238.22 · 5Y $348.77 · 10Y $517.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 37.2x C+ · PEG 1.44 B
Why now. The bull case hinges on the rapid adoption of the Omnipod 5 automated insulin delivery system, which is unlocking a 31.9% YoY revenue growth and translating into a healthy 10.4% profit margin. Management is converting that top‑line surge into cash, delivering $416 m of free cash flow and a robust ROE of 23.2%, giving the business the runway to compound earnings at a pace that matches our model’s perfect 100‑point Growth pillar. The thesis rests on the persistence of this compounding engine as the Omnipod platform expands globally.
Moat. Insulet’s moat derives from the integrated Omnipod ecosystem—an AID algorithm embedded in a disposable pod that pairs wirelessly with any third‑party CGM, creating a lock‑in for patients who value seamless, pump‑free therapy. The high ROE of 23.2% reflects pricing power that stems from this differentiated, prescription‑only technology, which competitors cannot replicate quickly without costly FDA approvals and manufacturing re‑tooling.
Risk. The bear case centers on the premium valuation: a forward P/E of 37.2 is lofty for a medical‑device growth name, and the implied 20% annual free‑cash‑flow growth from our reverse‑DCF is already below the 31.9% revenue expansion, suggesting the market may be over‑optimistic about margin sustainability. A slowdown in adoption of the Omnipod 5 or a pricing squeeze would push the P/E even higher, and a breach of the 0.78 debt‑to‑equity ratio could trigger credit concerns. The first sign of trouble would be a quarterly earnings miss that forces the price below the 52‑week low of $138.79.
Horizon. 1-3 yr $238.22 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $348.77 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $517.38 if current growth sustains into durable earnings power.
23. DECK — Deckers Outdoor Corporation · score 78.8
Footwear & Accessories · price $102.47 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.6x A- · PEG 1.28 B
Why now. The bull case hinges on the HOKA brand’s premium‑pricing power in the high‑performance running segment, which is driving a 9.8% YoY revenue growth and a 18.7% profit margin. Coupled with a stellar ROE of 41% and our model’s Quality pillar of 96, the business is a high‑quality compounder that can keep earnings expanding as consumers stay locked into premium outdoor footwear. The thesis rests on the ability to sustain this compounding margin and growth trajectory.
Moat. Deckers’ moat comes from its tightly integrated brand‑distribution engine: UGG, HOKA, Teva and Koolaburra each command premium pricing and sell through a curated network of specialty retailers that are costly for rivals to replicate. The 41% ROE reflects pricing power derived from category leadership in premium outdoor and lifestyle shoes, while a low debt‑to‑equity of 0.15 gives the company financial flexibility to reinvest in product innovation and share buybacks without diluting shareholders.
Risk. The bear case centers on the risk that revenue growth decelerates as the running and outdoor markets saturate, with the current 9.8% growth already above the 3% implied free‑cash‑flow growth baked into today’s price. A slowdown to sub‑5% would compress margins and make the 14.6× P/E appear stretched, while a beta of 1.17 amplifies downside in a volatile equity environment. A sustained miss on growth would trigger a sell‑off and invalidate the compounding narrative.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
24. FIVE — Five Below, Inc. · score 78
Specialty Retail · price $204.87 · 1Y $260.48 · 5Y $381.36 · 10Y $565.73
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 25.9x C+ · PEG 0.98 B+
Why now. The Bull Rankings model gives FIVE a Quality‑Growth score of 78, with Growth as the strongest pillar, and the thesis hinges on its rapid expansion of the novelty‑decor and party‑goods aisle that fuels a 25.9% YoY revenue growth. Management is converting that top‑line momentum into solid cash, delivering $505 m of free cash flow and a healthy 8.7% profit margin, which together support a forward‑looking valuation that still leaves upside. The entire case rests on the ability to keep compounding revenue at mid‑20% rates as the teen‑and‑young‑adult demographic continues to gravitate toward affordable, on‑trend accessories.
Moat. Five Below’s moat derives from its tightly curated assortment of low‑price novelty décor, party supplies, and lifestyle accessories that attract price‑sensitive Gen‑Z shoppers who visit weekly for new drops, creating a high‑frequency traffic loop that rivals can’t replicate without similar supplier relationships and store footprint. This stickiness translates into a ROE of 19%, driven by pricing power in a niche where few competitors can match the blend of product breadth and rapid turnover.
Risk. The bear case focuses on the elevated valuation metrics: a forward PE of 25.9× and a PEG of 0.98 imply the market already expects near‑term growth to accelerate, while the reverse‑DCF suggests a required 13% annual free‑cash‑flow growth—well below the current 25.9% revenue growth, indicating optimism is baked in. Rising leverage (debt‑to‑equity 0.86) and a beta of 1 amplify downside if consumer spending stalls, and a breach of the 13% FCF growth threshold would trigger a re‑rating.
Horizon. 1-3 yr $260.48 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.36 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $565.73 if current growth sustains into durable earnings power.
25. CRDO — Credo Technology Group Holding Ltd · score 76.7
Semiconductors · price $228.27 · 1Y $279.29 · 5Y $408.90 · 10Y $606.58
FCF $407m C · Rev +205.7% A · D/E 0.01 A · P/E 90.9x C · PEG 0.44 A
Why now. Credo’s ZeroFlap (ZF) active cables and OmniConnect memory solutions are riding the data‑center bandwidth boom, delivering 205.7% YoY revenue growth, 35.4% profit margin, and $407 m of free cash flow—a rare combination of speed and profitability. The explosive top‑line growth, backed by ultra‑high‑margin Ethernet and PCIe products, means earnings will keep compounding as hyperscale cloud operators double‑down on low‑latency interconnects. The thesis hinges on sustaining this growth trajectory.
Moat. Credo’s moat stems from its proprietary SerDes IP licensing and tightly integrated ZF optical transceivers, which lock customers into a high‑performance ecosystem that is costly to replace. With an ROE of 22.9%, the company extracts pricing power from being a preferred supplier for mission‑critical data‑center connectivity, and its near‑zero debt (D/E 0.01) gives it financial flexibility to reinvest in R&D without diluting shareholders.
Risk. The stock trades at a lofty PE of 90.9 and a beta of 3.2, implying market‑wide volatility and an over‑optimistic valuation that may not survive a slowdown in the data‑center spend cycle. Our model flags diluting shareholders, and any earnings miss would trigger a rapid price correction. A breach of the 52‑week high of $308.67 would confirm that the premium is unsustainable.
Horizon. 1-3 yr $279.29 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $408.90 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $606.58 if current growth sustains into durable earnings power.
26. NFLX — Netflix, Inc. · score 76.7
Entertainment · price $68.53 · 1Y $95.28 · 5Y $139.50 · 10Y $206.94
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B · P/E 21.6x B · PEG 1.54 C+
Why now. Netflix’s unrivaled global streaming library fuels a compounding engine that will keep subscriber spend rising, anchored by $11.2B of free cash flow, 45.3% ROE and 16% year‑over‑year revenue growth. Our Bull Rankings model gives NFLX a Quality‑growth score of 76.7, with Quality at 92, underscoring the durability of its high‑margin content franchise. The reverse‑DCF implies ~27% FCF growth for a decade—well above the 16% revenue pace—so the market already prices in aggressive optimism, leaving upside if the company sustains its premium pricing and expands its gaming and live‑programming slate.
Moat. The moat lies in Netflix’s massive, data‑driven content catalog delivered on every internet‑connected device, creating a stickiness that locks in subscribers and gives the firm pricing power that drives a ROE of 45.3%. Its algorithmic recommendation engine and original productions raise switching costs, while the sheer scale of its global subscriber base makes it prohibitively expensive for rivals to match content breadth and personalization.
Risk. The bear case centers on the lofty valuation and volatility: a forward P/E of 21.6 for a growth name, a beta of 1.52 and debt‑to‑equity at 0.55 signal sensitivity to a macro slowdown or a pricing pull‑back. If revenue growth stalls below the 16% trend and free cash flow growth falls short of the 27% implied by the reverse‑DCF, the stock could retreat toward its 52‑week low of $65.08.
Horizon. 1-3 yr $95.28 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $139.50 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $206.94 if current growth sustains into durable earnings power.
27. YUMC — Yum China Holdings, Inc. · score 76.6
Restaurants · price $43.42 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.6x B+ · PEG 1.07 B+
Why now. Yum China's dominant KFC franchise in China is accelerating digital ordering, driving a 6.7% YoY revenue growth and delivering a robust $931m free cash flow. Coupled with a solid PE of 16.6 and a 21‑analyst consensus 1‑yr target of $61.34, the company’s high‑quality operations (Quality pillar 83) underpin a compounding earnings engine that should keep cash generation expanding well beyond the reverse‑DCF implied 5% growth rate.
Moat. The KFC and Pizza Hut brands give Yum China a massive, city‑level footprint that locks in repeat traffic and leverages its proprietary delivery platform, creating a cost advantage that sustains a 17.4% ROE. This scale lets the firm negotiate favorable supply terms and roll out localized menu innovations faster than any new entrant, cementing its pricing power in the fast‑food market.
Risk. The stock trades at a premium to its 52‑week high of $58.39, implying that the consensus $61.34 target assumes a near‑term earnings acceleration that may be hard to achieve if competition intensifies or consumer spending stalls, which would compress the 7.8% profit margin and erode the upside. A breach of the $58.39 level would signal that the bull thesis is in trouble.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
28. FISV — Fiserv, Inc. · score 75.9
Sector n/a · price $50.22 · 1Y $67.19 · 5Y $84.82 · 10Y $108.78
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.5x A- · PEG 2.36 C
Why now. Sector n/a · market cap $26.8b. Down 65% from 52-week high of $144.18 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.19 (implying +34% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 65% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.19 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $84.82 at ~11% CAGR — dividend + buyback compounding. 10 yr $108.78 if the moat survives secular pressure.
29. EME — EMCOR Group, Inc. · score 74.8
Engineering & Construction · price $755.15 · 1Y $991.57 · 5Y $1,252 · 10Y $1,605
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 25.3x B+ · PEG 0.40 A
Why now. Engineering & Construction · market cap $33.6b. Down 21% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $991.57 (implying +31% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $991.57 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,252 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,605 if the moat survives secular pressure.
30. ULTA — Ulta Beauty, Inc. · score 74.7
Specialty Retail · price $483.52 · 1Y $623.42 · 5Y $912.74 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 18.1x B+ · PEG 1.70 C+
Why now. Specialty Retail · market cap $20.8b. Down 32% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.42 (implying +29% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.74 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.